Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...

Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial intelligence (AI) partnership aimed at discovering and developing up to 20 ...

Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop ...

Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial intelligence to drug discovery – adding up to nine programmes to the ...

Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and cardiometabolic diseases, leveraging AI and extensive human datasets.

Bagsværd, Denmark and Lexington, Massachusetts, US, 8 January 2025 – Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop ...

The company states: “Novo Nordisk (NVO) A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 ...

Novo Nordisk NOVO.B2.14%increase; green up pointing triangle expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human ...

Jan 8 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for ...

Danish drugmaker Novo Nordisk (NVO) (OTCPK:NONOF) and AI-focused biotech Valo Health announced Wednesday an agreement to expand their existing collaboration to discover and develop new treatments ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug programmes in obesity, type 2 diabetes, and cardiovascular ...